Buspirone Tapering Strategy
Buspirone 7.5 mg twice daily can be safely discontinued without a formal taper in most patients, as buspirone does not cause physical dependence or withdrawal symptoms, unlike benzodiazepines.
Key Evidence on Buspirone Discontinuation
The FDA drug label and clinical research provide clear guidance that buspirone differs fundamentally from benzodiazepines in its discontinuation profile 1, 2:
- No withdrawal syndrome: A multicenter study of 264 patients who completed one year of buspirone treatment found that abrupt discontinuation after more than six months of therapy yielded "no evidence of a withdrawal syndrome or unusual events" 2
- Non-addictive profile: Buspirone does not cause tolerance, addiction, or physical dependence—the hallmarks that necessitate tapering with benzodiazepines 3
- Short half-life: With an elimination half-life of approximately 2.5 hours, buspirone clears the system rapidly without accumulation 4
Recommended Discontinuation Approach
For Most Patients (Standard Approach)
Simply stop the medication. At 7.5 mg twice daily (15 mg total daily dose), you are already at the starting dose range. Abrupt discontinuation is safe and evidence-based 2.
For Cautious Patients or Those With Anxiety About Stopping
If the patient expresses concern or you prefer a conservative approach:
- Reduce to 5 mg twice daily for 3-7 days
- Then discontinue completely
This brief step-down is not medically necessary but may provide psychological reassurance.
Critical Distinctions From Other Anxiolytics
Do not confuse buspirone with benzodiazepines. The evidence about gradual tapering (25% dose reduction every 1-2 weeks) found in the guidelines applies specifically to benzodiazepines, which carry serious withdrawal risks including seizures, delirium tremens, and death 5, 6, 5. Buspirone requires no such precautions 2.
The guideline references to "discontinuing an antidepressant over 10 to 14 days" 3 also do not apply to buspirone, which is an anxiolytic with a completely different mechanism of action and discontinuation profile.
Clinical Monitoring
After discontinuation, monitor for:
- Return of original anxiety symptoms (not withdrawal, but recurrence of the underlying condition)
- Need for alternative anxiety management (consider CBT, SSRIs, or other evidence-based treatments if anxiety returns)
The patient should understand that any anxiety experienced after stopping is likely their baseline anxiety disorder, not a withdrawal effect, since buspirone takes 2-4 weeks to become effective and has no withdrawal syndrome 3.
Common Pitfall to Avoid
Do not apply benzodiazepine tapering protocols to buspirone. This unnecessarily prolongs discontinuation and may create nocebo effects where patients expect withdrawal symptoms that won't occur. The evidence is clear: buspirone can be stopped abruptly without medical risk 2.